Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

Abstract Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and
bioactivation of about 25% of clinically used drugs including many antidepressants …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate
pharmacogenetics implementation in clinical practice by developing evidence-based …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application
into routine care remains limited. Opportunely, several implementation studies and …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here,
presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and …

This article provides nomenclature recommendations developed by an international
workgroup to increase transparency and standardization of pharmacogenetic (PGx) result …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx
implementation by developing evidence-based pharmacogenetics guidelines to optimize …

Pre‐emptive pharmacogenetics (PG x) testing of a panel of germline genetic variants
represents a new model for personalized medicine. Clinical impact of PG x testing is …